Beyond chatbots – harnessing the power of artificial intelligence in the life sciences sector
The global healthcare AI market was valued at US$ 4.8 billion in 2019 and is projected to reach US$ 99.5 billion by 2027. The CAGR in this time frame is estimated to be 42.8%.
The opportunity in this emerging sector is massive, and early adopters will have a distinct advantage, but pharmaceutical companies are facing challenges when it comes to AI adoption.
The Edmonton region has unique strengths in the areas of both AI research and drug discovery and this session will provide an overview of this interesting intersection and share information about some of the exciting things taking place in the Edmonton region’s Health AI ecosystem.
WHAT ATTENDEES CAN EXPECT TO LEARN
Global strategic context – A global perspective on the intersection of AI and drug research and development and what that means for the future of this industry
Industry perspective – An industry perspective on how AI can solve some of the challenges around commercializing research and accelerate the scalability of businesses operating in this space.
Market overview – Identification and analysis some of the key problems pharmaceutical firms are facing around AI adoption (and how the Edmonton region stacks up)
- Access to talent
- Knowledge gap
- Availability of data
- Regulatory environment
Fanny Sie, One Roche Head of Artificial Intelligence and Digital Health, Roche
Fanny will share information covering the topic of innovative collaboration models by highlighting how the Roche Data Science Coalition led to the launch of the Roche AI Centre of Excellence in collaboration with the institutes of the Pan-Canadian AI strategy.
Dr. John Mackey, Professor and Director, Clinical Trials, Department of Oncology, Division of Medical Oncology
Dr Mackey is a medical oncologist at the Cross Cancer Institute in Edmonton, Canada, and a Professor of Oncology at the University of Alberta. He is also the co-founder of Pacylex Pharmaceuticals, J2 Endeavours, and SMHeartCard Inc., and serves on the board of directors of illumiSonics Inc. As Chair of the the Alberta Pre-Phase I Program steering committee, he leads a highly skilled team committed to bringing new anticancer therapies into clinical testing (www.prephaseone.com). He’s also authored or co-authored more than 300 biomedical peer reviewed publications.
Michael Wilson, CEO, DrugBank
DrugBank is the largest online database of drug and drug target information, used by researchers and customers in the drug development and precision medicine space. DrugBank is a curated pharmaceutical knowledge base, with products commercially available for precision medicine, telehealth, and drug discovery.
Jessica Cao, VP of Data Science and Information Technology at 48Hour Discovery
Founded in 2017, 48Hour Discovery (48HD) is a Canadian biotechnology company with headquarters in Edmonton, AB and satellite sites in San Diego, California and Seoul, South Korea. The 48HD genetically-encoded platform technology offers rapid discovery of pharmaceutical leads in the peptide / macrocycle therapeutic space.48Hour Discovery will be opening a new round of investment in quarter four of this year to accelerate our internal drug program.